Following the EPHESUS trial in 2003, mineralocorticoid receptor antagonist (MRA) therapy received a class I indication for the management of eligible high-risk post-MI patients. Our goal was to examine temporal trends in MRA use in eligible post-myocardial infarction (MI) patients.We investigated temporal trends and factors associated with MRA utilization among eligible patients enrolled in the biannual Acute Coronary Syndrome Israeli Surveys (ACSIS) 2004-2010.Among 7696 patients enrolled in the ACSIS surveys from 2004, 955 (12

作者：Edward, Koifman；Eran, Kopel；Elad, Maor；Paul, Fefer；Shlomi, Matezky；Goeffrey, Tofler；Ashraf, Hamdan；Ehud, Grossman；Ilan, Goldenberg；Robert, Klempfner

来源：International journal of cardiology 2013 年 168卷 4期